Proteoglycans contribute to extracellular matrix remodeling in asthmatic airways. We investigated the effects of budesonide, a glucocorticoid, and formoterol, a long-acting ß 2 -adrenergic agonist, on serum-induced proteoglycan production by human lung fibroblasts. In 10% serum, total proteoglycan production was increased 1.5-fold (p<0.01) compared to basal production in 0.4% serum. Budesonide (10 -8 M) reduced this increase by 44% (p<0.01), and while formoterol (10 -10 -10 -8 M) had no inhibitory effects, the drug combination abolished the increase (p<0.01) without affecting fibroblast proliferation. This synergistic effect required functional glucocorticoid and -adrenergic receptors. The production of the proteoglycans decorin, biglycan, perlecan, and versican, was increased 2.5-5-fold (p<0.01) in 10% serum.
Introduction
Lung fibroblasts are the principal source of collagens, glycoproteins, and proteoglycans, molecules that constitute airway extracellular matrix (ECM) and levels of which are elevated in the subepithelial tissue of asthmatic patients (1) (2) (3) . The increased deposition of ECM components in asthmatic airways is associated with an increase in the number of activated fibroblasts, known as myofibroblasts (4, 5) . It has been shown that an allergen challenge leads to a rapid increase in fibroblast activation and myofibroblast formation (6, 7) with upregulated synthesis of ECM components, contributing to the structural remodeling in the airways of patients with asthma (6) . Such increased deposition of ECM molecules in asthmatic airways is probably driven by ongoing inflammatory processes and is boosted by acute asthma episodes.
In turn, an altered ECM may perpetuate the inflammatory process (8) . One fundamental feature of inflammation is an increase in plasma exudation, a process in which plasma leaks out of blood vessels, thereby exposing the extravascular tissue to various plasma components.
This may provide an important innate stimulus for rapid inflammatory responses to allergens, irritants, and infections (9, 10). Indeed, elevated concentrations of various serum proteins were observed in bronchoalveolar lavage fluid and induced sputum from asthmatics exposed to allergens or other stimuli (11) (12) (13) , and an increased albumin level in bronchoalveolar lavage fluid was found to be the best predictor of prolonged bronchial inflammation (11) .
Moreover, it was shown that the concentration of albumin in induced sputum correlates with asthma symptoms (14) and asthma severity (15) , as well as several other hallmarks of asthmatic airway inflammation (14, 15) . In addition, various in vitro studies have shown that serum is a potent cell stimulator that increases fibroblast proliferation and ECM synthesis (16) (17) (18) and may thereby promote airway ECM remodeling.
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Several clinical studies have revealed that, in patients with asthma, treatment with an inhaled glucocorticoid (GC) and a long-acting 2 -agonist (LABA) provides better asthma control, including fewer disease exacerbations, than with a GC alone (19) (20) (21) . It is conceivable that the reduction in asthma exacerbations is a consequence of enhanced anti-inflammatory efficacy (22) , together with greater relaxation and lesser proliferation of bronchial smooth muscle cells (23, 24) , induced by the GC and LABA combination. Less is known about the potential of combined GC and LABA treatment to regulate the ECM remodeling and fibrotic processes in asthma that seem to be relatively resistant to therapy with inhaled GC (25, 26) . ECM remodeling is a crucial target for asthma pharmacotherapy because abnormal ECM structure may contribute to pathological alterations in the mechanics, reactivity, and function of asthmatic airways. Accordingly, bronchial subepithelial fibrosis was shown to be positively correlated with airway hyperresponsiveness and asthma severity (27, 28) .
Essential elements for airway and lung ECM homeostasis are the proteoglycans -a family of proteins covalently linked with glycosaminoglycans. They have diverse functions as a result of their structural heterogeneity, such as different sulfation patterns of the glycosaminoglycan chains, in addition to differences in the amino acid sequence of the core protein.
Proteoglycans have both structural and regulatory properties that affect not only fluid balance and tissue mechanics, but also activities of cytokines and growth factors, as well as various cellular functions (29) . Proteoglycans are known to participate in a range of biological processes including inflammation, wound healing, and fibrosis. Several studies have revealed that versican, biglycan, perlecan, and decorin are hallmarks of early and/or late progression of the ECM remodeling seen in asthma (1) (2) (3) 30) . A positive correlation has been found between the deposition of versican and biglycan in the subepithelial layer of the airway wall and airway hyperresponsiveness in asthmatic patients (3) . Similarly, in vitro production of 5 5 perlecan and biglycan by bronchial fibroblasts isolated from the airways of asthmatics was positively correlated with the donors' airway hyperresponsiveness (30) .
Given the importance of increased proteoglycan deposition in the ECM remodeling seen in asthmatic airways, we undertook the present study to examine (i) whether proteoglycan production by activated lung fibroblasts is affected by treatment with a combination of GC and LABA, and (ii) whether combination therapy has the potential to provide better control over proteoglycan upregulation than either drug alone. We studied the effects of budesonide (BUD), a GC, and formoterol (FORM), a LABA, alone and in combination, on both total and specific proteoglycan production in cultured human lung fibroblasts stimulated with donor calf serum. 
Study Design
Experiments were performed on lung fibroblasts cultured in 96, 24, or 6-well plates in Earle's minimal essential medium (Sigma-Aldrich, Irvine, UK) containing 10% (v/v) donor calf serum, 1% glutamine, and 5% penicillin-streptomycin at 37 ºC in a humidified 5% CO 2 atmosphere.
Total proteoglycan production was measured as [ To determine whether the effects of BUD and FORM on the total proteoglycan production were mediated via the GC and -adrenergic receptor respectively, the antagonists, mifepristone (10 -6 M) and propranolol (10 -7 M), were used as co-treatments with drugs.
The effects of BUD (10 -8 M) and FORM (10 -10 M), separately and in combination, on the production of various specific proteoglycans were further investigated at both protein and, in separate experiments, at mRNA levels. To examine whether these drugs inhibited the proteoglycan production directly or by affecting the cell proliferation, the effects of BUD and FORM on fibroblast proliferation were further investigated in the presence of 10% serum. All experiments were performed with duplicate or triplicate samples, and were repeated at least 3 times. 
Labeling and Extraction of Proteoglycans

Proteoglycan Isolation
Collected cell media were applied to columns of DEAE cellulose (Whatman, Maidstone, UK), 
Proteoglycan Identification
Following the isolation process, equal volumes of total proteoglycan fractions obtained were precipitated with 3 volumes of 95% ethanol with 0.4% acetic acid. Pellets were dried and dissolved in 0.1 M Tris-acetate pH 7.3 followed by separation using sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE). Electrophoresis was performed on 3-12% gradient gel using a 3% stacking gel. The gels were fixed in acetate:methanol:water (ratio 
Protein Determination
The production of proteoglycans was related to the corresponding cell layer's total amount of protein, which was determined using BCA TM protein assay kit (Pierce Chemical Co., Rockford, IL, USA). Bovine serum albumin was used as a standard.
RNA isolation and Complementary DNA synthesis
Total RNA was extracted from cells incubated with combinations of BUD and FORM, as described above, using RNeasy kit (Quagen GmgH, Hilden, Germany), according to the manufacturer's instructions. Quantity and purity of total isolated RNA was measured spectrophotometrically using a NanoDrop ND-1000 (NanoDrop technologies, Delaware, USA). To produce first strand cDNA, 100 ng of RNA was used for Reverse Transcriptase- analyzed using the lightcycler software. After normalization to the housekeeping gene 18S, relative mRNA expression was calculated from differences in threshold cycle, at which the fluorescence curve reaches its second derivate maximum. All real time-PCRs were performed in duplicates or triplicates. As a negative control for the cDNA, mRNA samples were used which had not undergone reverse transcription.
Oligonucleotide primers for real time-PCR
All primers used were generated using the oligonucleotide design program Primer3 (MIT) (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi), except for versican (33) , and ordered from A/S DNA Technology, Denmark. The product size of all primers ranged between 100-160 base pair. Biglycan, forward 5´-gga ctc tgt cac acc cac ct-3´ and reverse 5´-agc tcg gag atg tcg ttg tt-3´; decorin, forward 5´-tgg caa caa aatbcag cag ag-3´ and reverse 5´-gcc att gtc aac agc aga ga-3´; perlecan, forward 5´-ggc ata cga tgg ctt gtc tc -3´and reverse 5´-agc cag cat gtc ctc atc at-3´;18S, forward 5´-cga acg tct gcc cta tca ac -3´ and reverse 5`-tgc ctt cct tgg atg tgg ta-3´.
Cell Proliferation
HFL-1 cells were allowed to grow for 5 hours in a 96-well plate ( For additional control, fibroblast proliferation (for cells grown in 24-or 6-well plates) was also assayed in separate experiments, in which DNA was quantified using a modified fluorometric assay (35) with Hoechst 33258 dye (Riedel-de Haën, Hannover, Germany).
DNA was determined by excitation at 356 nm and emission at 458 nm and the amount was then calculated using a known standard for bovine DNA. 
Results
Effects of BUD and FORM on Total Proteoglycan Production
The total proteoglycan production by human lung fibroblasts, measured by [ 35 S]-sulfate incorporation, was increased 1.5-fold (p<0.01) in the presence of 10% serum compared with basal conditions (0.4% serum). BUD at 10 -8 M reduced this increase by 44% (p<0.01), whereas lower concentrations had no effect ( Figure 1A ). Higher concentration of BUD (10 -7 M) resulted in a 23% reduction but it did not reach statistical significance. Similarly, BUD at 10 -6 M (complementary experiment, n=2, data not shown), showed no greater inhibition than
FORM exerted rather inconsistent effects on serum-induced proteoglycan production. When using concentration 10 -9 M, FORM increased proteoglycan production by 51% (p<0.05), and a slight but not significant increase was also observed at 10 -8 M. At concentrations 10 -12 M-10 -10 M and 10 -7 M, there was an overall but not significant reduction of 7-30% ( Figure 1A ).
Even at 10 -6 M (complementary experiment n=2, data not shown), the reducing effect of FORM was not greater than that seen at FORM 10 -7 M.
To examine the effects of BUD and FORM in combination, we combined BUD 10 -8 M with equal and lower concentrations of FORM (10 -10 M-10 -8 M). All combinations inhibited the 10% serum-induced total proteoglycan production down to the level seen under low serum conditions (p<0.01) (no significant difference versus 0.4% serum level; Figure 1A ). The inhibitory effects of the combinations were generally significantly greater than the effects of the same concentrations of either drug alone, except for the combination of BUD 10 -8 M and FORM 10 -9 M. In this case, the 84% reduction by the combination was not significantly propranolol (10 -7 M), had no effect on its own, but reduced the inhibitory effect of the combination of BUD and FORM to the level of BUD alone ( Figure 1B) . These results indicate that the synergistic effect of FORM on BUD-mediated inhibition of proteoglycan production, as shown in Figure 1A , depends on the presence of functional GC andadrenergic receptors.
Additionally, the effects of the drugs were also examined on the basal proteoglycan production at 0.4% serum. While BUD 10 -8 M tended to decrease the proteoglycan production and FORM 10 -10 M to increase it, these effects were not statistically significant. The same drug concentrations in combination resulted in a modest (13%) but significant decrease (p<0.05; data not shown).
In separate series of experiments we examined the effects of BUD and FORM on total proteoglycan production measured as [ 3 H]-leucine incorporation into proteoglycan core proteins. The data obtained (insert in Figure 1A ) were similar to those described above using 
Effects of BUD and FORM on Individual Proteoglycan Production
In order to examine whether BUD and FORM differentially affected specific proteoglycans, a part of the fraction containing total proteoglycan amount was subjected to SDS-PAGE and separated into versican, perlecan, biglycan, and decorin ( Figure 2A ). The production of these proteoglycans was significantly increased in the presence of 10% serum compared with the production under low serum conditions ( Figure 2B) ; versican was increased 5.2 fold (p<0.01) whereas perlecan, biglycan, and decorin were increased 2.6-3.0-fold (p<0.01 for all). BUD 10 -8 M significantly decreased the production of versican, perlecan, and biglycan by 62%, 35%, and 50%, respectively (p<0.01 for all), but not of decorin production, where the 28% reduction was not statistically significant ( Figure 2B ). FORM 10 -10 M significantly decreased the decorin production by 35% (p<0.05), and reduced the production of the other proteoglycans to a similar extent as BUD. The combination of BUD and FORM significantly decreased the production of versican by 98% (p<0.01) and decorin by 85% and completely inhibited perlecan and biglycan (p<0.01 for both). Statistically, all drug combinations reduced the proteoglycan production to levels that were not significantly different from the basal levels, i.e. those seen under low serum conditions. The inhibitory effects of the combination treatment were approximately additive for the serum-induced production of versican and biglycan, and synergistic for perlecan and decorin ( Figure 2B ). For all proteoglycans studied, the effect of the drug combination was significantly greater than the effects of either drug alone.
Effects of BUD and FORM on Individual Proteoglycan mRNA expression
Real time-PCR experiments were performed to determine whether the changes in proteoglycan synthesis seen after treatment with BUD and FORM involved effects on mRNA Similarly, biglycan mRNA tended to increase 1.3-fold (p<0.1); this increase was completely prevented by the combination of BUD 10 -8 M and FORM 10 -10 M (p<0.05) but the 48% and 28% reductions seen with the single respective doses were not statistically significant. The 10% serum induction of perlecan mRNA expression was not statistically significant and drug treatments had no effect. The overall p-values from ANOVA were not significant for versican, biglycan and perlecan. In contrast to other proteoglycans studied, decorin mRNA expression in 10% serum was reduced to 39% of the basal expression in 0.4% serum (p<0.01; Figure 3 ). BUD at 10 -8 M alone, and in combination with FORM 10 -10 M, partly counteracted this effect reducing it by 25% (p<0.05) and 37% (p<0.01), respectively. FORM alone had no effect and there was no significant difference between the effects of BUD alone and in combination with FORM.
Effects of BUD and FORM on Fibroblast Proliferation
Following 24-hour incubation in 10% serum, the fibroblast proliferation increased 31% 
Discussion
We have demonstrated that proteoglycan production in cultured human lung fibroblasts, when serum-induced, is inhibited by treatment with BUD and FORM in combination. While BUD alone only modestly decreased the total proteoglycan production, and FORM had no inhibitory effects, when combined, FORM significantly enhanced the effect of BUD -a synergistic effect, that was shown to be dependent on functional GC and -adrenergic receptors. Regarding the individual proteoglycans studied -versican, perlecan, biglycan and decorin -both BUD and FORM alone had similar inhibitory effects, but an enhanced and complete inhibition was seen with the drugs in combination. Furthermore, we have shown that BUD and FORM, either alone or in combination, decreased proteoglycan production per se, and this was achieved predominantly on post-transcriptional level, and not by affecting fibroblast proliferation.
We measured total proteoglycan production by . This reflects the fact that, in asthma therapy, LABA doses are typically 10-100 times lower than GC doses, but also that multiple inhalations of short-acting 2 -agonists for symptom relief during asthma exacerbations may result in equal doses of 2 -agonists and GC.
In our study, fibroblasts were stimulated with 10% donor calf serum, which contains high concentrations of various active components, including growth factors and hormones, hence its use as a cell activator in various cell systems. Stimulation with serum resulted in an enhancement of both fibroblast proliferation and proteoglycan production. After normalization to protein content, the increase in the individual proteoglycans examined was greater than that in the total proteoglycan production. Besides experimental variation between separate series of experiments, this difference may be explained by the fact that fibroblasts produce and secrete several proteoglycans but not all of them are increased upon stimulation (41) , and some may even be decreased (42) . In fact, we have observed, at mRNA level, differential regulation of the proteoglycans, where serum stimulation resulted in a slight increase of versican and biglycan whereas decorin mRNA was reduced. Noteworthy, a pattern similar to that in our study, where induction of proteoglycan mRNA was lower than the induction of proteoglycans, and where an upregulation of decorin was accompanied by a downregulation of its mRNA, was also observed in human lung fibroblasts stimulated with TGF- (43) . The slight increase of the proteoglycans' mRNA by serum, accompanied by the several-fold increase of proteoglycans measured, suggests that serum increased proteoglycan production predominantly at post-transcriptional level.
Regarding the effects of drug treatments, BUD and FORM inhibited serum-induced total and individual proteoglycan production in an additive and synergistic manner. BUD partially decreased both the total and the individual proteoglycan production. FORM, on the other hand, had no significant inhibitory effects on the total production but it decreased the individual proteoglycans to a degree similar to BUD. This inconsistency in FORM effect suggests that there might be a pool of proteoglycans that are not inhibited by FORM, and may even be increased. However, at mRNA level, FORM had no effects on the individual proteoglycans except for a decrease of versican expression. Interestingly, BUD alone and in combination with FORM significantly counteracted both serum-induced increase of versican mRNA as well as the decrease of decorin mRNA. Similar action was earlier shown for dexamethasone that reduced TGF--induced increase of biglycan mRNA and prevented a decrease of decorin mRNA in human skin fibroblasts (44) . When comparing effects of the 20 20 drugs at protein (Fig. 2B ) and mRNA level (Fig. 3) , it seems that BUD and FORM regulate serum-induced proteoglycan production predominantly at post-transcriptional level, for example by increased proteolytic degradation.
In our study, the synergistic inhibition of serum-induced proteoglycan production by the BUD and FORM combination was due to the inhibition of fibroblast proteoglycan production and not to any effects on cell proliferation. BUD and FORM combination tended to decrease fibroblast proliferation although this effect was not statistically significant. A decrease in fibroblast proliferation has been observed by another combination of the GC fluticasone propionate and the LABA salmeterol) (45) .
There have been several reports on the co-operating inhibitory effects of GC and LABA on various activation markers of cultured human lung fibroblasts (45, 46) . Most recently, it was demonstrated that salmeterol enhanced the inhibitory effect of fluticasone propionate on the hyaluronan production induced in fibroblasts by IL-1 and TNF- (47) . Similarly, preliminary results from ongoing experiments in our laboratory show enhanced inhibition by the combination of BUD and FORM on TGF-1-induced proteoglycan production in lung fibroblasts (48) . Additive and synergistic effects of GC and LABA have also been described in airway smooth muscle cells (22, 23) .
The mechanisms of the interactions between GC and LABA are not completely elucidated, and may be specific to cell, stimulus, and/or response studied. However, there is an increasing was also demonstrated very recently, in a human study (51) . On the other hand, many of the effects of LABA in particular, but also of GC, have been reported to be independent of theadrenergic receptor (52) and classic, nuclear GC receptor (53), respectively. Therefore, we investigated the effects of receptor antagonists and showed that the inhibitory effects of BUD were mediated via the GC receptor, while the synergistic effects of BUD and FORM in combination were dependent on both the GC and -adrenergic receptors. Paradoxically, mifepristone -which blocked the effects of both BUD alone and BUD and FORM in combination -had its own inhibitory effect when applied alone; it is known, however, that mifepristone may sometimes act in vitro as a receptor agonist. The inhibitory effect of FORM on the individual proteoglycan production remains to be elucidated. However, it has been suggested that the anti-fibrotic effects of -agonists in serum-stimulated lung fibroblasts are mediated via the cyclic adenosine monophosphate pathway (18) .
The specific proteoglycans investigated in this study have been reported to be involved in the early or late processes of ECM remodeling in the asthmatic airways (1-3, 30, 54) as well as in lung fibrosis and other diseases with fibrotic tissue remodeling as a characteristic feature (54).
Versican, a large chondroitin sulfate proteoglycan, forms large aggregates with hyaluronic acid and therefore has an impact on fluid balance and tissue mechanics. Perlecan, a heparan sulfate, is a basal lamina proteoglycan; it regulates stability and permeability of basement membrane, and binds and activates the basic fibroblast growth factor that promotes angiogenesis (55) . Versican, and the two small chondroitin/dermatan sulfate proteoglycans biglycan and decorin, directly and indirectly affect cell responses to growth factors and cytokines, in addition to cell phenotype, proliferation, and migration (56) . Versican and biglycan are implicated early in airway remodeling, since increased levels of these 22 22 components are observed in the airways of patients with mild asthma (3). In contrast, decorin, although structurally related to biglycan, appears to be involved to a greater extent in a later phase of the airway remodeling process (1, 54) . Interestingly, decorin has been reported to have anti-fibrotic activity under certain conditions in vivo (57) . On the other hand, decorin is associated with the increased deposition of collagens type I and III (58) , and is co-localized with TGF-in asthmatic airways (59) . Recent studies have shown that cells treated with decorin differentiate into myofibroblasts with increased production of -smooth muscle actin, proteoglycans, and collagen type I (60, 61) . These data suggest that decorin may be involved in generating a more fibrotic ECM type. Our in vitro findings on the inhibition of decorin production by the combination of BUD and FORM were recently confirmed in vivo in a mouse model of asthma, where inhaled allergen induced a 10-fold increase of decorin in the epithelial basement membrane and submucosa of bronchi and bronchioles (62) .
In summary, we have demonstrated that total proteoglycan production in cultured human lung fibroblasts is modestly inhibited by BUD and that this effect is synergistically enhanced by the addition of FORM. We have also shown that the combination of BUD and FORM is more efficient than either drug alone in the inhibition of versican, biglycan, and perlecan (proteoglycans known as markers of an early inflammatory ECM), as well as decorin (which is usually upregulated in the more fibrotic ECM). The drug effects were exerted primarily at post-transcriptional level. We conclude that increased early and late deposition of proteoglycans in asthmatic airways may be limited by treatment with a combination of BUD and FORM. Clinical studies are warranted to confirm these conclusions. 
